Meeting Banner
Abstract #2955

Functional cardiac MRI for monitoring progression of hypertrophic cardiomyopathy in Mybpc3 mouse models

Min-Chi Ku1,2, Till Huelnhagen1, Saskia Schlossarek3,4, Andreas Pohlmann1, Lucie Carrier3,4, and Thoralf Niendorf1,2,5

1Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany, 2DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany, 3Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 4DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany, 5Experimental and Clinical Research Center, Charite Medical Faculty and the Max Delbrueck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Mutations in gene MYBPC3, encoding cardiac myosin-binding protein C, cause hypertrophic cardiomyopathy (HCM), which is characterized by left ventricular hypertrophy (LVH), diastolic dysfunction, increased interstitial fibrosis, and may lead to sudden cardiac death and heart failure. In spite of the advances in translational medicine, we know very little about HCM. The HCM progression is complex and shows heterogeneous phenotypes. The missing linkage of in vivo imaging and pathology has hindered the investigation of detail mechanisms of HCM. We therefore investigated Mybpc3-targeted mouse models using CMR markers for understanding HCM pathophysiology and to get closer to complete pictures of HCM progression.

This abstract and the presentation materials are available to members only; a login is required.

Join Here